Common questions about Esmya (FAQ)
Q: Why is Esmya used for fibroids before surgery?
A: Official documents state that ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids. This includes use as a pre-operative treatment before surgical removal of the fibroids. Its purpose is described as helping manage symptoms like heavy bleeding and achieving a reduction in fibroid volume, according to regulatory indications.
Q: Is Esmya the same type of drug as birth control pills?
A: No, Esmya is not classified as a standard birth control pill. It is a Selective Progesterone Receptor Modulator (SPRM), which means it selectively targets hormone receptors. Official product information notes that hormonal contraceptives containing progestogen may interfere with how Esmya works, meaning they are not recommended for use together.
Q: What happens when I stop taking Esmya?
A: Studies and official information indicate that menstrual cycles generally resume within 4 weeks of completing a treatment course. Any changes to the uterine lining, known as PAEC (Progesterone Receptor Modulator Associated Endometrial Changes), are expected to spontaneously reverse after stopping the medicine.
Q: How quickly does Esmya start affecting fibroid symptoms?
A: Esmya is intended to reduce menstrual blood loss and fibroid size. For the symptom of heavy bleeding, official documents note that the absence of menses (amenorrhea) is often observed within the first 10 days of starting treatment.
Q: Is Esmya a hormone therapy drug?
A: Ulipristal acetate is classified as a Selective Progesterone Receptor Modulator (SPRM), which is a type of sex hormone and modulator of the genital system. This means the drug targets and modulates specific hormone receptors in the body.
Q: Are there specific foods or drinks to avoid while taking Esmya?
A: Official product information notes an interaction concern with foods or drinks that inhibit the CYP3A4 enzyme in the liver. Grapefruit juice is one such example, and its use is described in product information as generally not recommended during treatment.
Q: What is the risk of my fibroids returning after finishing Esmya treatment?
A: Clinical study data have examined the time to recurrence of heavy bleeding symptoms after a treatment course is stopped. Research also suggests that the reduction in fibroid volume achieved during the treatment course persisted for at least 6 months after treatment.
Q: Is it normal to have spotting or breakthrough bleeding while on Esmya?
A: Amenorrhea, or the cessation of menses, is a very common expected effect of Esmya treatment. While cessation of bleeding is expected, the regulatory safety profile lists uterine haemorrhage as an uncommon side effect.
Q: Is Esmya a temporary solution, or can it shrink fibroids permanently?
A: The therapy is administered in defined, intermittent cycles of up to 3 months. While the drug is described as reducing fibroid size, regulatory documents do not contain claims that the shrinkage is permanent.
Q: What are the main differences between Esmya and GnRH agonists?
A: Clinical research has compared the efficacy and tolerability profile of ulipristal acetate with other active treatments, such as the GnRH agonist leuprolide acetate. These studies contribute to the overall understanding of ulipristal acetate’s mechanism and clinical application.
Q: Why is a pregnancy test required before starting Esmya?
A: Official regulatory information states that the medicine is contraindicated, meaning it must not be used, during pregnancy. Additionally, treatment is required to be initiated during the first week of menstruation, making it necessary to exclude pregnancy beforehand.
Q: Are headaches a temporary or long-term side effect of Esmya?
A: Headache is listed in official documents as a very common adverse reaction during treatment. However, regulatory sources do not classify it as being a temporary effect or a long-term effect.
Q: Can Esmya be used if I have allergies to other medications?
A: The medicine is officially contraindicated in cases of known hypersensitivity, or allergy, to the active substance (ulipristal acetate) or any of its inactive ingredients (excipients). Official product information does not list allergies to other, unrelated medications as a contraindication.
Q: Are there any reported interactions between Esmya and herbal supplements?
A: Official product information notes a specific concern regarding drugs that induce the CYP3A4 liver enzyme. The herbal remedy St John’s wort (Hypericum perforatum) is an example of a drug in this category and its use is described as not recommended with Esmya.
Q: How long does the uterine lining change (endometrial thickening) usually last after stopping Esmya?
A: The specific changes to the uterine lining, known as PAEC, reverse spontaneously after the medication is withdrawn. This reversal is noted to occur once menstruation begins following the end of the treatment course.
Q: Why is Esmya sometimes prescribed for up to four cycles?
A: Official regulatory approval is based on clinical trials that investigated and authorized repeated intermittent treatment. The medicine is indicated for up to four intermittent 3-month treatment courses.
Q: Is Esmya a chemotherapy drug?
A: No, Esmya is not classified as a chemotherapy drug or a cytotoxic agent. Ulipristal acetate is formally classified as a Selective Progesterone Receptor Modulator (SPRM), which acts by modulating hormone receptors.
Q: Can I take Esmya if I have kidney problems?
A: Official regulatory information states that no dose adjustment is necessary for individuals with mild or moderate kidney impairment. However, the medicine is generally not recommended in patients who have severe renal impairment unless they are closely monitored.
Q: What should I know about taking Esmya if I'm planning a pregnancy soon?
A: Esmya is contraindicated during pregnancy, and official product information indicates that fertility is likely to return quickly after stopping the treatment. Official product information notes that a reliable, non-hormonal barrier method of contraception is recommended during treatment and for 12 days after the course ends.
Q: Is it common for doctors to monitor fibroid size during Esmya treatment?
A: The treatment must be initiated and supervised by a physician experienced in the diagnosis and treatment of uterine fibroids. Clinical studies have monitored the reduction in fibroid volume as an outcome. This monitoring is typically part of the physician’s supervision for uterine fibroid treatment.
Q: Why is Esmya not available in some countries anymore?
A: The regulatory indication for ulipristal acetate 5mg has been restricted in some regions following a safety review. Official regulatory bodies have released safety updates concerning a rare risk of serious liver injury and liver failure.
Q: Is Esmya used for all sizes or types of uterine fibroids?
A: Clinical trials that supported regulatory approval focused on patients whose largest fibroid measured between 3 cm and 12 cm in diameter. The studies also included women whose uterus size was no larger than that of a 16-week pregnancy.
Q: Is the Esmya treatment protocol different for women over 40?
A: The safety and effectiveness of Esmya were established in adult women aged 18 years and older. Regulatory documents indicate that there are no specific protocol adjustments or different doses based solely on age, excluding post-menopausal women.
Q: Does Esmya have any effect on bone density?
A: Official clinical data indicates that ulipristal acetate does not appear to impact bone turnover. Studies suggest it maintains oestradiol levels within the mid-follicular range, which supports the finding of no adverse impact on bone density.
